𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Protective effect of protease inhibitors in influenza virus infected animals

✍ Scribed by O. P. Zhirnov; A. V. Ovcharenko; A. G. Bukrinskaya

Publisher
Springer Vienna
Year
1982
Tongue
English
Weight
797 KB
Volume
73
Category
Article
ISSN
1432-8798

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

High protection of animals lethally infe
High protection of animals lethally infected with influenza virus by aprotinin-rimantadine combination
✍ Oleg P. Zhirnov πŸ“‚ Article πŸ“… 1987 πŸ› John Wiley and Sons 🌐 English βš– 490 KB

The successful therapeutic synergism of aprotinin and rimantadine, which are known to attack different viral targets, was demonstrated in influenza-virusinfected animals. Combined treatment with these drugs of mice infected with a highly lethal dose of mouse-adapted influenza virus prevented the dev

Effects of combining selected inhibitors
Effects of combining selected inhibitors of influenza virus replication in tissue culture
✍ K. S. Pilcher; J. M. Bowen πŸ“‚ Article πŸ“… 1965 πŸ› John Wiley and Sons 🌐 English βš– 409 KB

When certain compounds-mostly antimetabolites inhibitory to influenza virus replication in tissue culture-were combined in various ways, the virus inhibition was enhanced in a s nergistic manner with many o f the combinations studied. The selectivit of this ingibitory effect also was increased signi

Characterization of resistance to the pr
Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus–infected patients
✍ Simone Susser; Christoph Welsch; Yalan Wang; Markus Zettler; Francisco S. Doming πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 543 KB

Boceprevir is a hepatitis C virus (HCV) nonstructural protein (NS) 3/4A protease inhibitor that is currently being evaluated in combination with peginterferon alfa-2b and ribavirin in phase 3 studies. The clinical resistance profile of boceprevir is not characterized in detail so far. The NS3 protea